European treatment guidelines; Nationalpolicies; Optimal access to care; Standard of care
Indexed keywords
ABACAVIR PLUS LAMIVUDINE;
AMPRENAVIR PHOSPHATE;
ATAZANAVIR;
DIDANOSINE;
EFAVIRENZ;
EMTRICITABINE;
EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
LAMIVUDINE;
LAMIVUDINE PLUS ZIDOVUDINE;
LOPINAVIR PLUS RITONAVIR;
NEVIRAPINE;
PROTEINASE INHIBITOR;
RITONAVIR;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
SAQUINAVIR;
ZIDOVUDINE;
ADULT;
ARTICLE;
CLINICAL PRACTICE;
DRUG CONTRAINDICATION;
DRUG INDICATION;
DRUG POTENTIATION;
DRUG TREATMENT FAILURE;
EUROPE;
HEALTH CARE ACCESS;
HEALTH CARE AVAILABILITY;
HEALTH CARE PLANNING;
HEALTH CARE QUALITY;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
MATERNAL TREATMENT;
PATIENT ASSESSMENT;
PATIENT CARE;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
PUBLIC HEALTH SERVICE;
SEROLOGY;
SINGLE DRUG DOSE;
VIRUS VIRULENCE;
ADULT;
ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;
DIAGNOSIS, DIFFERENTIAL;
EUROPE;
FEMALE;
HIV INFECTIONS;
HUMANS;
MEDICAL HISTORY TAKING;
OCCUPATIONAL DISEASES;
PREGNANCY;
PREGNANCY COMPLICATIONS, INFECTIOUS;
REFERRAL AND CONSULTATION;
TREATMENT FAILURE;
Estimating the optimum CD4 threshold for starting HAART antiretroviral-naïve HIV-infected individuals
February Denver, Colorado [Abstract 525]
Sterne J, May M, Costagliola D et al. Estimating the optimum CD4 threshold for starting HAART antiretroviral-naïve HIV-infected individuals. 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colorado [Abstract 525].
Association between CD4 and HIV RNA with non AIDS-related causes of death in the era of combination antiretroviral therapy (cART)
July Sydney, Australia [Abstract WEPEB019]
Marin B, Thiébaut R, Rondeau V et al. Association between CD4 and HIV RNA with non AIDS-related causes of death in the era of combination antiretroviral therapy (cART). Third International AIDS Society Conference of HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia [Abstract WEPEB019].
Prognosis of HIV1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies
Egger M, May M, Chene G et al. Prognosis of HIV1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.
Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naïve individuals and those treated in the monotherapy era
Phillips A. CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naïve individuals and those treated in the monotherapy era. AIDS 2004; 18: 51-58.
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-260.
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral drug classes
Ledergerber B, Lundgren JD, Walker AS et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral drug classes. Lancet 2004; 364: 51-62.
US Department of Health and Human Services. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission
Use of antiretroviral agents in HIV-infected adults in the United States. Rockville, MD: HIV/AIDS Treatment Information Service. Available
US Department of Health and Human Services. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission. Use of antiretroviral agents in HIV-infected adults in the United States. Rockville, MD: HIV/AIDS Treatment Information Service. Available http://AIDSinfo.nih.gov
8
11244315078
Post-sexual-exposure chemoprophylaxis (PEP) for HIV: A prospective cohort study of behavioral impact
Chicago, Illinois, February [Abstract 225]
Harrison LH, Do Lago RF, Moreira RI, Mendelsohn AB, Schechter Ml. Post-sexual-exposure chemoprophylaxis (PEP) for HIV: A prospective cohort study of behavioral impact. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 4-8, 2001 [Abstract 225].
Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV
Schechter M, Do Lago RF, Mendelsohn AB et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. JAIDS 2004; 35: 519-525.
Tolerability of post-exposure prophylaxis of HIV infection with the combination of zidovudine/lamivudine and lopinavir/ritonavir (Combivir+Kaletra)
Rabaud C, Burty C, Grandidier M et al. Tolerability of post-exposure prophylaxis of HIV infection with the combination of zidovudine/ lamivudine and lopinavir/ritonavir (Combivir+Kaletra). Clin Infect Dis 2005; 40: 303-305.
